Top Page
HitIQ Limited
(Sydney:HIQ)
HitIQ Limited (HIQ) vs. iShares MSCI Australia ETF (EWA)
HitIQ Limited Business Overview & Revenue Model
HitIQ Limited Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.01M | 2.01M | 4.75M | 774.26K | 619.02K | 406.68K |
| Gross Profit | -2.18M | -2.18M | 334.63K | 242.73K | 243.43K | -3.28M |
| EBITDA | -5.99M | -5.99M | -2.54M | -4.31M | -6.54M | -4.79M |
| Net Income | -7.21M | -7.21M | -3.20M | -5.04M | -6.95M | -5.06M |
Balance Sheet | ||||||
| Total Assets | 3.28M | 3.28M | 3.73M | 3.13M | 4.55M | 9.49M |
| Cash, Cash Equivalents and Short-Term Investments | 990.96K | 990.96K | 584.02K | 1.98M | 2.94M | 8.96M |
| Total Debt | 5.66M | 5.66M | 3.20M | 1.69M | 2.16M | 709.34K |
| Total Liabilities | 7.30M | 7.30M | 5.20M | 3.18M | 3.38M | 1.56M |
| Stockholders Equity | -4.02M | -4.02M | -1.47M | -46.86K | 1.17M | 7.92M |
Cash Flow | ||||||
| Free Cash Flow | -4.68M | -4.68M | -4.12M | -4.57M | -6.57M | -2.18M |
| Operating Cash Flow | -4.65M | -4.65M | -4.10M | -4.51M | -6.51M | -2.13M |
| Investing Cash Flow | -28.57K | -28.57K | -20.78K | -54.73K | -918.06K | -54.84K |
| Financing Cash Flow | 5.09M | 5.09M | 2.73M | 3.61M | 1.41M | 10.71M |
HitIQ Limited Technical Analysis
HitIQ Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | AU$46.78M | -8.29 | -81.30% | ― | -36.68% | 79.41% | |
48 Neutral | AU$22.32M | -12.37 | -17.05% | ― | 28.91% | -1050.00% | |
44 Neutral | AU$16.17M | -5.42 | ― | ― | 241.34% | 44.19% | |
43 Neutral | AU$77.34M | -10.79 | ― | ― | ― | ― | |
41 Neutral | AU$4.53M | -5.17 | ― | ― | -9.90% | 34.07% | |
40 Underperform | AU$9.56M | -1.03 | ― | ― | -40.05% | -49.57% |
HitIQ Limited Corporate Events
HitIQ Limited has applied for quotation on the ASX of 2,772,728 new fully paid ordinary shares, to be traded under its existing ticker HIQ. The securities, issued on 19 January 2026 as part of previously announced transactions, will increase the company’s quoted share capital, potentially enhancing liquidity for investors and supporting HitIQ’s ongoing capital management initiatives.
The most recent analyst rating on (AU:HIQ) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on HitIQ Limited stock, see the AU:HIQ Stock Forecast page.
HitIQ Limited has announced plans to issue up to 2,772,728 new fully paid ordinary shares via a placement. The proposed capital raising, to be completed on 19 January 2026, is intended to expand the company’s issued capital base and may support its ongoing operational or growth initiatives, with implications for existing shareholders through equity dilution and potential strengthening of the balance sheet.
The most recent analyst rating on (AU:HIQ) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on HitIQ Limited stock, see the AU:HIQ Stock Forecast page.
HITIQ Limited has chosen to preserve cash by settling a $50,000 investor relations fee owed to Spark Plus Pte Ltd through the issuance of 2,272,728 ordinary shares at a deemed price of A$0.022 per share, aligned with its most recent capital raising. The company has also issued 500,000 shares to ambassador Nathan Murphy under his agreement, with all new shares to be issued from HITIQ’s existing ASX Listing Rule 7.1 placement capacity, a move that modestly dilutes existing shareholders while supporting ongoing operational and promotional activities without additional cash outlay.
The most recent analyst rating on (AU:HIQ) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on HitIQ Limited stock, see the AU:HIQ Stock Forecast page.
HitIQ Limited has called a hybrid General Meeting of shareholders for 11:00am AEDT on Friday, 6 February 2026, allowing investors to participate either in person at the company’s South Melbourne office or online, where they can watch, ask questions and vote. In line with updated Corporations Act requirements, the company will not mail physical copies of the Notice of Meeting and Explanatory Statement, instead directing shareholders to access these documents via its share registry, ASX company page or website, and strongly encouraging proxy voting ahead of the meeting, reflecting an ongoing shift toward digital governance and shareholder engagement practices.
The most recent analyst rating on (AU:HIQ) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on HitIQ Limited stock, see the AU:HIQ Stock Forecast page.
HitIQ Limited has called a general meeting of shareholders for 11:00am (AEDT) on Friday, 6 February 2026 in South Melbourne and online, and has outlined procedures for proxy appointment and voting ahead of the event. The proxy form details how investors can appoint the chair or another proxy, direct votes on a series of funding- and remuneration-related resolutions—including approval of share and option issues, ratification of prior placements, security arrangements with No Bull Health Pty Ltd, and issuance of securities to directors in lieu of fees—underscoring ongoing capital management and governance decisions that may affect shareholder dilution, director compensation structure and the company’s financing arrangements.
The most recent analyst rating on (AU:HIQ) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on HitIQ Limited stock, see the AU:HIQ Stock Forecast page.
HitIQ Limited has called a hybrid general meeting for 6 February 2026 to seek shareholder approval for a series of capital and financing measures that could significantly alter its ownership and security structure. The key proposal is the potential issue of up to 470.2 million new shares on conversion of convertible notes held by the Harmil Group, which, together with existing holdings, could lift Harmil’s voting power from 12.80% to as much as 53.86%, effectively handing it majority control if approved. Shareholders are also being asked to approve general and specific security interests in favour of No Bull Health Pty Ltd, an associate of major shareholder Harmil Angel Investments, as well as to ratify a prior placement of 40.9 million shares and 20.45 million free-attaching options at $0.022. Independent expert reports have been provided to assess whether these related-party and control transactions are fair and reasonable for non-associated shareholders, underscoring the governance and control implications for existing investors.
The most recent analyst rating on (AU:HIQ) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on HitIQ Limited stock, see the AU:HIQ Stock Forecast page.
HitIQ Limited has applied to the ASX for quotation of 6,181,818 options (ASX code HIQOA) expiring on 30 December 2028, with the securities issued as part of previously announced transactions. The move increases the number of listed options on issue and may provide additional liquidity and potential future capital for the company if the options are exercised, though no further operational or strategic details were disclosed in the filing.
The most recent analyst rating on (AU:HIQ) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on HitIQ Limited stock, see the AU:HIQ Stock Forecast page.
HitIQ Limited has applied to the ASX for quotation of 16,135,199 options (code HIQOA) expiring on 30 December 2028. The issuance, linked to previously announced transactions, increases the company’s listed option pool and may provide additional future capital if exercised, potentially affecting capital structure and dilution for existing shareholders.
The most recent analyst rating on (AU:HIQ) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on HitIQ Limited stock, see the AU:HIQ Stock Forecast page.
HITIQ Limited has partnered with Sportscover to integrate its PROTEQT™ concussion management system into Sportscover’s sports insurance offerings. This exclusive partnership introduces a claims-triggered cover feature, where Sportscover funds a PROTEQT™ unit for insured members upon a confirmed concussion claim. Initially launching with Hockey Australia, the collaboration aims to expand across Sportscover’s portfolio, providing community sports with professional-grade concussion management. This partnership positions Sportscover as a leader in player welfare and safety, offering a scalable approach to concussion management at the grassroots level.
The most recent analyst rating on (AU:HIQ) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on HitIQ Limited stock, see the AU:HIQ Stock Forecast page.
HITIQ Limited has clarified details regarding its recent partnership with Smith College, part of its US Collegiate Market Expansion. The contract is valued at USD $13,650, with a term of 24 months, and no other material conditions were noted. This agreement signifies HITIQ’s ongoing efforts to strengthen its presence in the US collegiate sports market, potentially enhancing its market positioning and stakeholder engagement.
The most recent analyst rating on (AU:HIQ) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on HitIQ Limited stock, see the AU:HIQ Stock Forecast page.
HITIQ Limited has been awarded a AUD $20,000 grant by the Australian Sports Commission to fund a pilot project, with the agreement effective upon execution and continuing until project completion. This grant supports HITIQ’s ongoing efforts in enhancing athlete safety and concussion management, potentially strengthening its position in the sports technology industry.
The most recent analyst rating on (AU:HIQ) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on HitIQ Limited stock, see the AU:HIQ Stock Forecast page.
HitIQ Limited has announced a successful placement, raising $900,000 through the issuance of 40,909,092 fully paid ordinary shares and 20,454,544 options. This capital raise is expected to enhance the company’s financial position and support its strategic initiatives in the sports technology sector.
The most recent analyst rating on (AU:HIQ) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on HitIQ Limited stock, see the AU:HIQ Stock Forecast page.
HitIQ Limited has announced the quotation of new securities on the Australian Securities Exchange (ASX), including 20,454,544 options expiring in December 2028 and 40,909,092 fully paid ordinary shares. This move is part of previously announced transactions and is expected to enhance the company’s financial positioning and market presence, potentially impacting stakeholders positively by increasing liquidity and investment opportunities.
The most recent analyst rating on (AU:HIQ) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on HitIQ Limited stock, see the AU:HIQ Stock Forecast page.
HITIQ Limited has completed the initial tranche of a placement, raising $900,000 before costs by issuing 40,909,092 ordinary shares at $0.022 each. The placement also includes one new listed option for every two shares, exercisable at $0.022 and expiring on 30 December 2028. Directors Tony Toohey and James Barrie have participated in the placement, with their involvement pending shareholder approval in January 2026. This development aligns with HITIQ’s ongoing efforts to strengthen its financial position and support its concussion management technology initiatives.
The most recent analyst rating on (AU:HIQ) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on HitIQ Limited stock, see the AU:HIQ Stock Forecast page.
HITIQ Limited has been awarded a prestigious grant from the Australian Sports Commission under ‘The Park’ innovation programme, which supports cutting-edge sports technology development. This grant will enable HITIQ to further develop and validate their PROTEQT™ technology within elite sporting environments, enhancing their market credibility and positioning them as a leader in athlete brain health protection across Australian sports. The initiative will also facilitate the adoption of their technology by National Sporting Organisations, Olympic and Paralympic sports, and community sports, contributing to the development of national safety standards and evidence-based policies for brain health.
The most recent analyst rating on (AU:HIQ) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on HitIQ Limited stock, see the AU:HIQ Stock Forecast page.
HITIQ Limited has announced the first deployment of its PROTEQT™ instrumented mouthguards in the United States, marking a significant expansion into the American collegiate sports research market. This strategic move involves a partnership with Smith College’s Motor Neuroscience and Neuroimaging Laboratory to study concussion risks in women’s rugby, an area with growing participation and institutional support. The collaboration positions PROTEQT™ as a key technology in concussion research, potentially influencing broader adoption across the US collegiate athletics market, which includes over 500,000 NCAA student-athletes.
The most recent analyst rating on (AU:HIQ) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on HitIQ Limited stock, see the AU:HIQ Stock Forecast page.
HitIQ Limited has announced a proposed issue of securities, including 29,431,818 options expiring on December 30, 2028, and 42,045,455 ordinary fully paid shares. This issuance is part of a strategic move to strengthen the company’s financial position and support its growth initiatives. The announcement reflects HitIQ’s commitment to expanding its market presence and enhancing its operational capabilities, which could have significant implications for its stakeholders and industry positioning.
The most recent analyst rating on (AU:HIQ) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on HitIQ Limited stock, see the AU:HIQ Stock Forecast page.
HITIQ Limited has successfully completed an oversubscribed placement, raising $925,000 from new and existing sophisticated investors. The funds will be used for the ongoing development and commercialization of its concussion management technology and general working capital. This capital raise, which follows a recent rights issue, positions HITIQ with a solid financial base as it heads into 2026, and underscores the growing momentum and investor confidence in its concussion management solutions.
The most recent analyst rating on (AU:HIQ) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on HitIQ Limited stock, see the AU:HIQ Stock Forecast page.
HitIQ Limited has requested a trading halt on its securities pending an announcement regarding a capital raising initiative. This move is intended to help the company manage its disclosure obligations and is expected to impact its financial operations, potentially influencing its market positioning and stakeholder interests.
The most recent analyst rating on (AU:HIQ) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on HitIQ Limited stock, see the AU:HIQ Stock Forecast page.
HitIQ Limited, listed on the ASX under the ticker HIQ, held its 2025 Annual General Meeting on Friday, 28 November. The meeting’s agenda included discussions on the 2025 financial statements, a poll on twelve resolutions, and an executive chair presentation, followed by a general Q&A session and refreshments. The event aimed to address key business matters and engage stakeholders in the company’s strategic direction.
The most recent analyst rating on (AU:HIQ) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on HitIQ Limited stock, see the AU:HIQ Stock Forecast page.
HITIQ Limited has announced the retail distribution of its PROTEQT™ concussion management system through rebel, Australia’s leading sporting goods retailer. This strategic move marks HITIQ’s entry into the consumer retail market, leveraging rebel’s extensive retail network and brand recognition. The collaboration with Shock Doctor has facilitated this transition, positioning PROTEQT™ for availability ahead of the 2026 sports season. This initiative aims to capture the growing demand for safety products in contact sports, driven by increased safety awareness and regulatory focus on athlete safety.
The most recent analyst rating on (AU:HIQ) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on HitIQ Limited stock, see the AU:HIQ Stock Forecast page.
HITIQ Limited has announced its strategic entry into the North American market through a partnership with Rick Shultz, who will serve as the exclusive distributor for PROTEQT™ mouthguards in Canada and hold non-exclusive rights in the United States. This move leverages Shultz’s extensive connections within the Canadian hockey ecosystem, aiming to capitalize on the country’s substantial hockey market, which is the second-largest globally. The partnership is expected to generate immediate revenue and support long-term growth, with a focus on both institutional and consumer channels to address the full spectrum of the market. The strategy underscores HITIQ’s commitment to expanding its presence in North America and meeting the growing demand for concussion management technology.
HitIQ Limited announced a change in the director’s interest notice involving Matthew Clayworth. The notice details adjustments in the number of securities held by Clayworth, primarily due to corrections of administrative errors and the expiration of certain options. This change reflects a routine update in the company’s governance and does not imply immediate operational or strategic shifts.
HitIQ Limited has announced the quotation of 400,000 ordinary fully paid securities on the Australian Securities Exchange (ASX) as of November 14, 2025. This move is part of their strategy to enhance liquidity and provide more opportunities for investors, potentially strengthening their position in the market and benefiting stakeholders by increasing the company’s visibility and capital resources.
HITIQ Limited’s PROTEQT™ technology has been selected for a major brain injury research program funded by the Australian Research Council (ARC) and led by Monash University. The project, which has secured a grant of $799,866, will utilize 400 PROTEQT™ units to study brain injury thresholds, combining biomechanics and biomarkers. This partnership not only provides immediate revenue but also positions HITIQ at the forefront of concussion research, potentially influencing global safety protocols and clinical guidelines. The collaboration enhances HITIQ’s reputation and supports its regulatory pathways, with implications for international adoption and validation of its technology.
HitIQ Limited announced the resignation of Philip Carulli as a director, effective October 31, 2025. The notice details Carulli’s interests in the company’s securities, including fully paid ordinary shares and listed options, indicating a significant stake. This change in directorship may impact the company’s governance and strategic direction, influencing stakeholder confidence and market perception.
HitIQ Limited has announced the appointment of Anthony (Tony) Peter Toohey as a director, effective from October 31, 2025. The company has disclosed that Mr. Toohey currently holds no relevant interests in securities, either as a registered holder or through contracts, indicating a fresh start in his role with the company.
HitIQ Limited has achieved significant milestones in the September 2025 quarter, including securing an order for 100 PROTEQT™ mouthguards for the Winter Olympics, marking its first Olympic deployment. The company is also undergoing an independent assessment by the International Federation of Sports Medicine (FIMS) for potential global adoption of its technology. Additionally, HitIQ has launched its product in the UK consumer market, integrating with NHS 111 telehealth services, and appointed former AFL player Nathan Murphy as a brand ambassador to enhance visibility in grassroots sports. These developments position HitIQ for broader international expansion and increased credibility in the sports safety industry.
HitIQ Limited has released a proxy voting form for its upcoming Annual General Meeting scheduled for November 28, 2025. The document outlines the procedures for shareholders to appoint proxies and vote on various resolutions, including the adoption of a remuneration report and the election of directors. This announcement is significant as it provides shareholders with the necessary information to participate in the governance of the company, potentially impacting future strategic decisions and company operations.
HitIQ Limited has announced its 2025 Annual General Meeting, which will be held on November 28, 2025, at 3.30pm AEDT. The meeting will be conducted in a hybrid format, allowing shareholders to participate either in-person or online, with provisions for pre-registration and proxy voting. This approach reflects the company’s commitment to accessibility and shareholder engagement, potentially strengthening its relationship with stakeholders.
HitIQ Limited has announced its upcoming Annual General Meeting, which will be held both online and in person. The meeting will address several key resolutions, including the adoption of the remuneration report, the election and re-election of directors, and the approval of a mandate to issue equity securities. These resolutions are crucial for the company’s governance and future strategic decisions, potentially impacting shareholder value and company operations.
HITIQ Limited announced the appointment of Tony Toohey as a Non-Executive Director, replacing Phil Carulli, effective October 31, 2025. This change marks a complete refresh of the Board since November 2023. Mr. Toohey brings extensive experience in gaming, hospitality, leisure, and technology industries, which is expected to enhance the company’s strategic oversight and growth as it pivots towards the consumer market. Mr. Carulli, who has been instrumental in the company’s journey from its inception to its IPO and commercialization of its concussion management system, will transition his accounting and bookkeeping services over the next three months. The leadership transition is seen as a strategic move to support HITIQ’s continued growth and success.